NewLeaf Brands (CSE: NLB) this morning announced that it has completed its wholly owned and operated R&D and product development lab in Denver, Colorado. The lab will be utilized by the firms Mydecine division for the purpose of researching mushrooms for human wellness.
The facility, 7,500 square feet in size, is said to include chemical analysis, genomic sequencing, purification and tissue culture capabilities. The lab is stated to be used for “fungtional mushrooms” and to research the healing potential of such products, lead by Mydecine CSO Rob Roscow and Dr Mali Reddy.
Naturally, the facility is located in Denver, Colorado as a result of the city decriminalizing psilocybin mushrooms in 2019. The move as a result “prohibits the city from spending resources to pursue criminal penalties related to the use and possession of psilocybin mushrooms among people 21 and older.” The company claims that the facilities will be the first of their type in North America as a result.
Given this, the lab is intended to be used to develop unique IP on exotic breeds of fungi. It should be noted however, that given the status of psilocybin on a state and federal level, its unclear that this IP will be able to be protected after development.
NewLeaf Brands last traded at $0.78 on the CSE.
Information for this briefing was found via Sedar, The State of Colorado, and NewLeaf Brands. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.
As the founder of The Deep Dive, Jay is focused on all aspects of the firm. This includes operations, as well as acting as the primary writer for The Deep Dive’s stock analysis. In addition to The Deep Dive, Jay performs freelance writing for a number of firms and has been published on Stockhouse.com and CannaInvestor Magazine among others.